R&D Partner Content 2nd LNP Immunogenicity & Toxicity Summit Back for its second iteration, the LNP Immunogenicity & Toxicity Summit (December 11-13, 2023 | Boston) will bring together 1
Views & Analysis Overcoming the challenges of developing vaccines in an accel... The COVID-19 pandemic stopped the world in its tracks.
Events Partner Content 2nd Gene Therapy Immunogenicity Modulate, Measure & Predict Immune Response to GTx
Partner Content Partner Content A Run Down of Keynote Sessions for Cell & Gene Therapy 2... Cell and Gene Therapy
Partner Content Partner Content Immuno-Oncology challenges include identifying patients befo... Challenges facing Immuno-Oncology industry
Events Partner Content SMi's 5th Annual Biosimilars USA Conference Biosimilars USA conference information
News GSK gets second cancer drug approval from Nuvalent buy The FDA has cleared GSK's ALK inhibitor Nelkarmi for a form of lung cancer, the second product from its $10.6bn acquisition of Nuvalent.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.